Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer

@inproceedings{Yuan2014CriticalAO,
  title={Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer},
  author={Ying Yuan and Xiao-fen Li and Jia-qi Chen and Cai-xia Dong and Shan-Shan Weng and Jian-jin Huang},
  booktitle={OncoTargets and therapy},
  year={2014}
}
Past studies have demonstrated that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors can significantly improve clinical outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and sensitive EGFR gene mutations. Gefitinib (Iressa(®)), the first oral EGFR tyrosine kinase inhibitor, has been shown to be more effective and better tolerated than chemotherapy either in first-line or second-line treatment for patients with advanced NSCLC harboring… CONTINUE READING
4 Citations
76 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 76 references

A phase II trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous NSCLC patients with wild-type EGFR (CTONG0806)

  • JJ Yang, Y Cheng, MF Zhao
  • J Clin Oncol
  • 2013

Similar Papers

Loading similar papers…